Join Jon and Pete Najarian on today's episode of Rebel's Edge as they discuss stocks including Fulcrum Therapeutics getting FDA clearance for phase one of their sickle cell disease treatment trials, Dick's dealing with inventory shrink, Macy's reporting reduced sales, and Fabrinet riding the AI wave. Gain a deeper understanding of these stocks as Jon and Pete share their perspectives, potential growth prospects, and market predictions. They also talk about the unstoppable Jalen Carter, and University of Michigan's self-imposed suspension of Head Coach Jim Harbaugh. Stay on the cutting edge with Rebel's Edge.
Learn more about options trading with Jon and Pete at: https://marketrebellion.com
